Yidu Tech Inc.

DB:0EL Stock Report

Market Cap: €587.4m

Yidu Tech Valuation

Is 0EL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0EL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0EL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0EL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0EL?

Key metric: As 0EL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0EL. This is calculated by dividing 0EL's market cap by their current revenue.
What is 0EL's PS Ratio?
PS Ratio5.7x
SalesCN¥780.04m
Market CapCN¥4.43b

Price to Sales Ratio vs Peers

How does 0EL's PS Ratio compare to its peers?

The above table shows the PS ratio for 0EL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
COP CompuGroup Medical SE KGaA
1x1.9%€1.1b
NXU Nexus
4.4x9.5%€1.2b
AJ91 DocCheck
0.8xn/a€43.6m
M3V MeVis Medical Solutions
2.6xn/a€46.2m
0EL Yidu Tech
5.7x15.8%€4.7b

Price-To-Sales vs Peers: 0EL is expensive based on its Price-To-Sales Ratio (5.7x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 0EL's PS Ratio compare vs other companies in the European Healthcare Services Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
0EL 5.7xIndustry Avg. 2.3xNo. of Companies10PS02.44.87.29.612+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0EL is expensive based on its Price-To-Sales Ratio (5.7x) compared to the European Healthcare Services industry average (2.3x).

Price to Sales Ratio vs Fair Ratio

What is 0EL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0EL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.7x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: 0EL is expensive based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0EL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.55
€0.75
+38.1%
21.8%€0.98€0.61n/a3
Dec ’25€0.65
€0.75
+15.8%
21.8%€0.98€0.61n/a3
Nov ’25€0.39
€0.77
+97.4%
17.1%€0.95€0.65n/a3
Oct ’25€0.42
€0.76
+78.5%
17.9%€0.95€0.64n/a3
Sep ’25€0.34
€0.76
+120.0%
17.9%€0.95€0.64n/a3
Aug ’25€0.37
€0.76
+103.5%
17.9%€0.95€0.64n/a3
Jul ’25€0.44
€0.77
+74.4%
16.7%€0.95€0.62n/a4
Jun ’25€0.47
€0.82
+75.1%
26.0%€1.17€0.62n/a4
May ’25€0.49
€0.82
+67.8%
26.3%€1.17€0.61n/a4
Apr ’25€0.46
€0.82
+77.2%
26.3%€1.17€0.61n/a4
Mar ’25€0.48
€0.82
+69.9%
26.3%€1.17€0.61n/a4
Feb ’25€0.37
€0.82
+119.9%
26.3%€1.17€0.61n/a4
Jan ’25€0.57
€0.82
+44.3%
26.3%€1.17€0.61€0.584
Dec ’24€0.55
€0.92
+66.4%
22.4%€1.18€0.61€0.655
Nov ’24€0.49
€1.03
+109.7%
30.9%€1.45€0.63€0.394
Oct ’24€0.47
€1.14
+143.6%
31.7%€1.58€0.62€0.425
Sep ’24€0.46
€1.15
+151.7%
32.0%€1.57€0.61€0.345
Aug ’24€0.64
€1.15
+79.3%
32.0%€1.57€0.61€0.375
Jul ’24€0.67
€1.63
+143.4%
42.2%€2.71€0.80€0.444
Jun ’24€0.60
€1.49
+147.5%
51.9%€2.82€0.63€0.475
May ’24€0.68
€1.62
+138.1%
46.1%€2.72€0.62€0.494
Apr ’24€0.85
€1.77
+108.4%
43.9%€2.84€0.65€0.464
Mar ’24€1.09
€1.77
+62.5%
43.9%€2.84€0.65€0.484
Feb ’24€0.83
€2.30
+176.0%
49.2%€3.73€0.65€0.374
Jan ’24€0.72
€2.73
+276.8%
51.7%€4.31€0.64€0.574

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 16:27
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yidu Tech Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Liping ZhaoChina International Capital Corporation Limited
Ruili BianCitigroup Inc
null nullCMB International Securities Limited